We observed that DADS treatment significantly mitigated the levels of glucose consumption, intracellular G6P levels, intracellular G6PD activities, but increased the NADP+/NADPH ratios in CRC cells (P<0.05, Figure 3D-H). This evidence concerns the gene G6PD and colorectal carcinoma.